AIMS: Presence of a relationship between autoimmunity and malignant diseases has been investigated for a long time. Anti-SS-B and anti-centromere protein (CENP)-B antibodies are used as serologic markers for autoimmune diseases. In this study, these autoantibodies were studied in breast cancer patients, and their effect on survival was evaluated. PATIENTS & METHODS: Breast cancer patients treated between January and June 2003 were prospectively included in this study. Antibodies were studied by ELISA, and serum values of greater than 10 U/ml were accepted as positive. RESULTS: In total, 55 patients with breast cancer were prospectively included in the study. Median follow-up time was 62 months. In univariate analysis, estrogen receptor status, anti-CENP-B antibody status and tumor size significantly affected disease-free survival, whereas overall survival was significantly dependent on tumor size and anti-CENP-B antibody status. In multivariate analysis, anti-CENP-B status was the independent prognostic factor for disease-free survival, whereas tumor size and anti-CENP-B status were independent prognostic factors for overall survival. CONCLUSION: Anti-CENP-B autoantibodies in breast cancer patients prolong disease-free and overall survival.
AIMS: Presence of a relationship between autoimmunity and malignant diseases has been investigated for a long time. Anti-SS-B and anti-centromere protein (CENP)-B antibodies are used as serologic markers for autoimmune diseases. In this study, these autoantibodies were studied in breast cancerpatients, and their effect on survival was evaluated. PATIENTS & METHODS:Breast cancerpatients treated between January and June 2003 were prospectively included in this study. Antibodies were studied by ELISA, and serum values of greater than 10 U/ml were accepted as positive. RESULTS: In total, 55 patients with breast cancer were prospectively included in the study. Median follow-up time was 62 months. In univariate analysis, estrogen receptor status, anti-CENP-B antibody status and tumor size significantly affected disease-free survival, whereas overall survival was significantly dependent on tumor size and anti-CENP-B antibody status. In multivariate analysis, anti-CENP-B status was the independent prognostic factor for disease-free survival, whereas tumor size and anti-CENP-B status were independent prognostic factors for overall survival. CONCLUSION: Anti-CENP-B autoantibodies in breast cancerpatientsprolong disease-free and overall survival.
Authors: Takeru Igusa; Laura K Hummers; Kala Visvanathan; Carrie Richardson; Fredrick M Wigley; Livia Casciola-Rosen; Antony Rosen; Ami A Shah Journal: Ann Rheum Dis Date: 2018-04-20 Impact factor: 19.103
Authors: Félix Fernández Madrid; Marie-Claire Maroun; Ofelia A Olivero; Michael Long; Azadeh Stark; Lawrence I Grossman; Walter Binder; Jingsheng Dong; Matthew Burke; S David Nathanson; Richard Zarbo; Dhananjay Chitale; Rocío Zeballos-Chávez; Carol Peebles Journal: BMC Cancer Date: 2015-05-15 Impact factor: 4.430